EUVIMEDEUVIMED entdecken
Crossref

Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma

Minghe Lv, Lei Tang, Liu Yang, Jingping Yu, Qing Ji, Ruping Zhao

Clinical and Translational Oncology · 14.10.2025 · 28 (4) · 1178-1197

DOI: 10.1007/s12094-025-04079-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 14.10.2025. Verfasst von Minghe Lv und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. 17211270006@fudan.edu.cn. Hauptthemen laut MEDLINE: Cisplatin, RNA, Long Noncoding, Drug Resistance, Neoplasm, Adenocarcinoma of Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: the Shanghai Health Commission, Science and technology development project of Shanghai University of Traditional Chinese Medicine, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cisplatin (CDDP) resistance represents an urgent clinical challenge. Identifying CDDP-resistant lung adenocarcinoma (LUAD) patients responsive to immunotherapy through novel biomarkers is critical for improving survival outcomes. METHODS: CDDP resistance genes were identified from RNA-seq data of A549 cells in the GEO database. RNA sequencing, genetic mutations, and clinical data of LUAD patients were obtained from TCGA. Patients were split into training and validation cohorts. A prognostic model was developed using LASSO and multivariate Cox regression, with validation in both cohorts. Tumor mutation burden (TMB), immune activity, and functional enrichment analyses (GO, KEGG) were performed to explore the link between lncRNA and CDDP resistance. RESULTS: Twenty-three CDDP resistance-associated genes were identified from GEO. Co-expression analysis revealed 507 CDDP resistance-linked lncRNAs. Cox regression analysis identified three CDDP resistance-related lncRNAs: ARAP1-AS2, LINC01843, and LINC02198. RT-PCR verified these lncRNAs and representative mRNAs (KIF21B, B3GNT3, PLXNA2). Patients stratified by median risk score showed significantly worse overall survival (OS) and higher mortality in high-risk groups. Univariate/multivariate Cox analyses confirmed the risk score as an independent prognostic factor. A nomogram predicted LUAD survival outcomes. Low-risk patients exhibited significantly lower TMB than high-risk counterparts, with low-risk/high-TMB patients showing optimal OS. The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm revealed significant differences in immune dysfunction, CD8+ T cells, cancer-associated fibroblasts (CAF), and tumor-associated macrophages (TAM-M2) between risk groups. CONCLUSION: These three CDDP resistance-associated lncRNAs including ARAP1-AS2, LINC01843, and LINC02198, serve as reliable prognostic biomarkers for LUAD. The findings provide insights for immunotherapeutic strategies and personalized treatment development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinRNA, Long NoncodingDrug Resistance, NeoplasmAdenocarcinoma of LungLung NeoplasmsAntineoplastic AgentsHumansPrognosisBiomarkers, TumorFemaleMaleA549 CellsMutation

Stichwörter der Autor:innen

CisplatinImmuneLncRNALung adenocarcinomaPrognosisResistance

Substanzen

CisplatinRNA, Long NoncodingBiomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Radiotherapy, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. 17211270006@fudan.edu.cn.
  • Department of Medical Oncology and Cancer Institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
  • Department of Oncology, Baoshan Branch, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
  • Shanghai Baoshan District Wusong Central Hospital (Zhongshan Hospital Wusong Branch, Fudan University), Shanghai, 200940, China.
  • Chengdu University of Traditional Chinese Medicine, Chendu, 610075, China.
  • Department of Radiotherapy, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

Förderung

  • the Shanghai Health Commission
  • Science and technology development project of Shanghai University of Traditional Chinese Medicine
  • National Natural Science Foundation of China

Zitieren

APA

Lv, M., Tang, L., Yang, L., Yu, J., Ji, Q., & Zhao, R. (2025). Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma. Clinical and Translational Oncology, 28(4), 1178-1197. https://doi.org/10.1007/s12094-025-04079-6

Vancouver

Lv M, Tang L, Yang L, Yu J, Ji Q, Zhao R. Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma. Clinical and Translational Oncology. 2025;28(4):1178-1197. doi:10.1007/s12094-025-04079-6

BibTeX
@article{Lv2025,
  author = {Lv, Minghe and Tang, Lei and Yang, Liu and Yu, Jingping and Ji, Qing and Zhao, Ruping},
  title = {Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma},
  journal = {Clinical and Translational Oncology},
  year = {2025},
  volume = {28},
  number = {4},
  pages = {1178--1197},
  doi = {10.1007/s12094-025-04079-6}
}
Kostenlos starten →